Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director · Bd. Co-Chair, President & CEO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 214,523 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 28,570 · Balance 243,093 Row 2 · 2025-12-31 · Tax withholding · Disposed 28,570 · Balance 214,523 |
| 2020 Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 595,077 |
Reported balance
After 2025-12-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-31 · Exercise / conversion · Disposed 28,570 · Balance 595,077 F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 127,484 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 127,484 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,989 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,989 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 39,985 |
Reported balance
Holding disclosure · report date 2025-12-31 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 39,985 |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 295 | $626.15 | $184,714.25 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 12 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 33,267 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 295 shares of Company stock on August 16, 2021 at prices ranging from $626.04 to $626.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,355 | $625.19 | $847,132.45 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 11 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 33,562 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 1,355 shares of Company stock on August 16, 2021 at prices ranging from $625.01 to $625.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,862 | $624.42 | $1,162,670.04 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 34,917 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 1,862 shares of Company stock on August 16, 2021 at prices ranging from $624.00 to $624.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,393 | $623.66 | $1,492,418.38 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 36,779 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 2,393 shares of Company stock on August 16, 2021 at prices ranging from $623.08 to $623.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 924 | $622.44 | $575,134.56 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 39,172 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 924 shares of Company stock on August 16, 2021 at prices ranging from $622.00 to $622.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 287 | $621.76 | $178,445.12 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,096 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 287 shares of Company stock on August 16, 2021 at prices ranging from $621.25 to $621.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 96 | $620.36 | $59,554.56 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,383 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 96 shares of Company stock on August 16, 2021 at prices ranging from $620.35 to $620.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 34 | $619.83 | $21,074.22 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,479 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 34 shares of Company stock on August 16, 2021 at prices ranging from $619.67 to $619.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 90 | $618.82 | $55,693.80 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,513 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 90 shares of Company stock on August 16, 2021 at prices ranging from $618.13 to $618.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 258 | $617.79 | $159,389.82 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,603 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 258 shares of Company stock on August 16, 2021 at prices ranging from $617.56 to $617.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 146 | $616.70 | $90,038.20 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,861 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 146 shares of Company stock on August 16, 2021 at prices ranging from $616.66 to $616.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:42 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 171 | $615.54 | $105,257.34 |
DisclosureSEC source: 0001708138-21-000058 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 41,007 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 171 shares of Company stock on August 16, 2021 at prices ranging from $615.35 to $615.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2021 at each separate price. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · derivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · derivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 240,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: With respect to 240,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 160,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 91,430 | $607.51 | $55,544,639.30 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,746 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 160,000 | $52.03 | $8,324,800.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 137,145 | $607.51 | $83,316,958.95 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,176 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 240,000 | $52.03 | $12,487,200.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 19, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 41,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by 2019 GRAT Disclosed balance after: 0 Read SEC document |
| May 19, 2021 Filed Aug 10, 2021 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 41,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000048 · edgardoc.xml · nonDerivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 41,178 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantPerformance Stock Units · Derivative | 620,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-000901 · tm211598-1_4seq1.xml · derivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,270 Underlying: Common Stock · 620,270 shares Expires not disclosed F1 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. F1 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. F1 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain total shareholder return ("TSR") goals derived from compound annual growth rates of 5.6% to 19.2% over a five-year performance period ending on December 31, 2025 (or in some cases at earlier times). Between 50% and 250% of the target number of 248,108 PSUs may be earned upon achievement of such TSR goals but shall only vest at the end of the five-year performance period if the reporting person's service to the Company continues through such date, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change in control ("CIC")). Earned PSUs are subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a CIC. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 638 | $577.27 | $368,298.26 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 25 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,499 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F22 · price: Represents volume-weighted average price of sales of 638 shares of Company stock on May 12, 2020 at prices ranging from $577.15 to $577.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,728 | $576.51 | $996,209.28 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 24 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,137 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 1,728 shares of Company stock on May 12, 2020 at prices ranging from $576.04 to $576.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,196 | $575.48 | $1,263,754.08 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 23 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,865 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 2,196 shares of Company stock on May 12, 2020 at prices ranging from $575.04 to $575.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,390 | $574.59 | $2,522,450.10 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 22 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,061 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 4,390 shares of Company stock on May 12, 2020 at prices ranging from $574.17 to $574.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,014 | $573.27 | $5,740,725.78 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 21 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,451 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 10,014 shares of Company stock on May 12, 2020 at prices ranging from $573.00 to $573.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19,984 | $572.47 | $11,440,240.48 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 20 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,465 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 19,984 shares of Company stock on May 12, 2020 at prices ranging from $572.00 to $572.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15,542 | $571.49 | $8,882,097.58 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 19 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,449 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 15,542 shares of Company stock on May 12, 2020 at prices ranging from $571.00 to $571.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 20,267 | $570.49 | $11,562,120.83 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 18 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,991 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 20,267 shares of Company stock on May 12, 2020 at prices ranging from $570.01 to $570.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19,982 | $569.52 | $11,380,148.64 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 17 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,258 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 19,982 shares of Company stock on May 12, 2020 at prices ranging from $569.00 to $569.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18,021 | $568.58 | $10,246,380.18 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 16 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,240 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 18,021 shares of Company stock on May 12, 2020 at prices ranging from $568.00 to $568.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 9,359 | $567.57 | $5,311,887.63 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 15 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,261 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 9,359 shares of Company stock on May 12, 2020 at prices ranging from $567.00 to $567.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,810 | $566.51 | $3,291,423.10 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 14 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,620 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 5,810 shares of Company stock on May 12, 2020 at prices ranging from $566.00 to $566.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,032 | $565.67 | $1,715,111.44 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 13 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,430 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 3,032 shares of Company stock on May 12, 2020 at prices ranging from $565.16 to $565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 779 | $564.41 | $439,675.39 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 12 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,462 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 779 shares of Company stock on May 12, 2020 at prices ranging from $564.01 to $564.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,549 | $563.51 | $1,436,386.99 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 11 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,241 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 2,549 shares of Company stock on May 12, 2020 at prices ranging from $563.12 to $563.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,394 | $562.75 | $784,473.50 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 10 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,790 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 1,394 shares of Company stock on May 12, 2020 at prices ranging from $562.33 to $562.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,994 | $561.24 | $2,241,592.56 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 9 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,184 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 3,994 shares of Company stock on May 12, 2020 at prices ranging from $561.00 to $561.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,391 | $560.68 | $1,901,265.88 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,178 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 3,391 shares of Company stock on May 12, 2020 at prices ranging from $560.19 to $560.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,361 | $559.52 | $761,506.72 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,569 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 1,361 shares of Company stock on May 12, 2020 at prices ranging from $559.02 to $559.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,162 | $558.35 | $2,323,852.70 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 6 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,930 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 4,162 shares of Company stock on May 12, 2020 at prices ranging from $558.00 to $558.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,329 | $557.51 | $1,298,440.79 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 5 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,092 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 2,329 shares of Company stock on May 12, 2020 at prices ranging from $557.02 to $557.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 12, 2020 at each separate price. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · derivative · entry 29 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,500 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F23 · derivative.exercise_date: With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · derivative · entry 28 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 125,000 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F23 · derivative.exercise_date: With respect to 125,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. With respect to 187,500 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 96,947 | $571.43 | $55,398,424.21 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 4 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,421 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 187,500 | $30.63 | $5,743,125.00 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 3 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 64,631 | $571.43 | $36,932,092.33 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 2 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,868 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 125,000 | $30.63 | $3,828,750.00 |
DisclosureSEC source: 0001708138-20-000058 · edgardoc.xml · nonDerivative · entry 1 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 187,500 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 8 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 187,500 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 124,900 | $0.00 Strike: $21.25 | $0.00 |
DisclosureSEC source: 0001237899-19-000031 · edgardoc.xml · derivative · entry 7 SCHLEIFER LEONARD S · CIK 0001218629 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 124,900 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.